Drug Efficacy And SafetyThe data from the OLE study MESA demonstrates continued BMD disease stabilization and stable to 0.8 pt improvement in NSAA, along with a continued favorable safety profile over 18-36 months, which is seen as continued support for the drug in BMD.
Drug Efficacy In HCMEWTX is already seeing very impressive improvements in how oHCM patients feel and function, with clinically meaningful improvements on both the Kansas City Cardiomyopathy Questionnaire and New York Heart Association class that clear the bar set by Phase 3 studies of cardiac myosin inhibitors at just 4 weeks.
Market PositionAnalyst views Edgewise Therapeutics as favorably positioned in its market segment.